AR116312A1 - Método mejorado para la fabricación de 3-[(1s)-1-imidazo[1,2-a]piridin-6-iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimórficas de la misma - Google Patents

Método mejorado para la fabricación de 3-[(1s)-1-imidazo[1,2-a]piridin-6-iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimórficas de la misma

Info

Publication number
AR116312A1
AR116312A1 ARP190102586A ARP190102586A AR116312A1 AR 116312 A1 AR116312 A1 AR 116312A1 AR P190102586 A ARP190102586 A AR P190102586A AR P190102586 A ARP190102586 A AR P190102586A AR 116312 A1 AR116312 A1 AR 116312A1
Authority
AR
Argentina
Prior art keywords
manufacture
triazolo
imidazo
pyridin
improved method
Prior art date
Application number
ARP190102586A
Other languages
English (en)
Inventor
Gareth Paul Howell
Andrew Timothy Turner
Andrew Roy Turner
Neil Keith Adlington
Keith Raymond Mulholland
Malcolm Allan Young Gall
Zhenping Tian
Wei Yu
Qisun Gong
Bo Liu
Original Assignee
Hutchison Medipharma Ltd
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd, Astrazeneca Ab filed Critical Hutchison Medipharma Ltd
Publication of AR116312A1 publication Critical patent/AR116312A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Esta memoria descripta se refiere generalmente a un método mejorado para la fabricación de 3-[(1S)-1-imidazo[1,2-a]piridin-6-iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina, de fórmula (1), o sales farmacéuticamente aceptables de la misma; formas polimórficas de la misma; e intermedios útiles en la fabricación de dichos compuestos y sales de los mismos.
ARP190102586A 2018-09-11 2019-09-11 Método mejorado para la fabricación de 3-[(1s)-1-imidazo[1,2-a]piridin-6-iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimórficas de la misma AR116312A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2018104941 2018-09-11

Publications (1)

Publication Number Publication Date
AR116312A1 true AR116312A1 (es) 2021-04-21

Family

ID=67988964

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102586A AR116312A1 (es) 2018-09-11 2019-09-11 Método mejorado para la fabricación de 3-[(1s)-1-imidazo[1,2-a]piridin-6-iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimórficas de la misma

Country Status (16)

Country Link
US (1) US20220048904A1 (es)
EP (1) EP3849977B1 (es)
JP (1) JP2022500494A (es)
KR (1) KR20210057777A (es)
CN (1) CN112930348B (es)
AR (1) AR116312A1 (es)
AU (1) AU2019340569B2 (es)
BR (1) BR112021003814A2 (es)
CA (1) CA3110762A1 (es)
CO (1) CO2021004130A2 (es)
EA (1) EA202190643A1 (es)
ES (1) ES2956847T3 (es)
IL (1) IL281283B2 (es)
MX (1) MX2021002794A (es)
TW (1) TWI833800B (es)
WO (1) WO2020053198A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301146A (en) 2020-09-28 2023-05-01 Codexis Inc Engineered biocatalysts and methods for the synthesis of chiral amines
GB202300923D0 (en) 2023-01-20 2023-03-08 Macfarlan Smith Ltd Novel polymorphic forms of savolitinib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1291356B1 (it) * 1997-05-13 1999-01-07 Zambon Spa Processo per la rimozione di metalli pesanti
AU2010338712B2 (en) * 2009-12-31 2015-04-02 Hutchison Medipharma Limited Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
CN107805648B (zh) * 2017-10-10 2020-09-11 凯莱英生命科学技术(天津)有限公司 制备具有多个手性中心的胺化合物的方法

Also Published As

Publication number Publication date
ES2956847T3 (es) 2023-12-29
CA3110762A1 (en) 2020-03-19
US20220048904A1 (en) 2022-02-17
BR112021003814A2 (pt) 2021-05-18
EA202190643A1 (ru) 2021-07-09
EP3849977A1 (en) 2021-07-21
AU2019340569B2 (en) 2022-06-09
IL281283B2 (en) 2024-01-01
EP3849977B1 (en) 2023-07-19
TWI833800B (zh) 2024-03-01
MX2021002794A (es) 2021-08-11
CN112930348B (zh) 2023-12-05
KR20210057777A (ko) 2021-05-21
JP2022500494A (ja) 2022-01-04
CO2021004130A2 (es) 2021-04-30
TW202026295A (zh) 2020-07-16
IL281283A (en) 2021-04-29
IL281283B1 (en) 2023-09-01
CN112930348A (zh) 2021-06-08
AU2019340569A1 (en) 2021-05-13
WO2020053198A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
UY37781A (es) Proceso para la preparación de pirazolo[1,5-a] pirimidinas y sales de las mismas
DK3523301T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
DK3523302T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
CO2022004686A2 (es) Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo
DK3419978T3 (da) Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
AR094943A1 (es) Pirimidas condensadas sustituidas con trifluorometilo
CL2018002533A1 (es) Procedimientos para el tratamiento de la depresíón usando antagonisdas de los receptores de orexina-2.
CL2014002220A1 (es) Compuesto 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido[2,3-d]pirimidin-6-il)fenil)urea, inhibidor de la cinasa raf; forma cristalina del compuesto; composicion farmaceutica que lo comprende; y metodo para tratar el cancer.
NI201400052A (es) Composiciones farmacéuticas de 7 - ( 6 - ( 2 - hidroxipropano - 2 - il ) piridina - 3 - il ) - 1 - ((trans) - 4 - metoxiciclohexil ) - 3, 4 - dihidropirazino [ 2, 3 - b ] pirazina - 2 ( 1h ) - ona, una forma sólida de las mismas y métodos de su uso
CO2021004130A2 (es) Método mejorado para la fabricación de 3-[(1s)-1-imidazo[1,2-a]piridin-6-iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimórficas de la misma
CL2016000496A1 (es) Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
CL2021000276A1 (es) Polimorfo cristalino del clorhidrato de 8-bromo-2-(1-metilpiperidin-4-ilamin)-4-(4-fenoxifenilamin)pirido[4,3-d]pirimidin-5(6h)-ona y método para prepararlo.
MX2018013133A (es) Compuesto de pirazolo[1,5-a]pirimidina.
DK3840832T3 (da) Imidazo[1,2-b]pyridaziner som trk-inhibitorer
DK3083627T3 (da) [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis
CO2019006234A2 (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal
DK3679042T3 (da) Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer
CL2018002344A1 (es) Proceso para preparar compuestos de 7h-pirrolo[2,3-d]pirimidina
CL2020002598A1 (es) Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida
CL2020001346A1 (es) Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción.
DK3823972T3 (da) Imidazo[1,2-b]pyridazinderivater som trk-inhibitorer
CO2021004061A2 (es) Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k)
DK3816164T3 (da) Isothiazolo[5,4-d]pyrimidin-forbindelse som irak4-inhibitor